Paper36765658
Evaluation of Anlotinib Combined with Adriamycin and Ifosfamide as Conversion Therapy for Unresectable Soft Tissue Sarcomas.
Long Z and 10 others. Cancers (Basel), 2023. Cited by 6 papers, by iCite.
Cite this record
ConductScience Library. Evaluation of Anlotinib Combined with Adriamycin and Ifosfamide as Conversion Therapy for Unresectable Soft Tissue Sarcomas. Papers, record 36765658. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/36765658
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Evaluation of Anlotinib Combined with Adriamycin and Ifosfamide as Conversion Therapy for Unresectable Soft Tissue Sarcomas.
- PubMed
Topics0
NLM's MeSH indexing of the paper, its major topics first.
None in this release.
References33
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 19097774 | New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). | Eur J Cancer | 2009 | https://conductscience.org/library/papers/19097774 | PubMed |
| 2 | 28656259 | Anti-angiogenesis target therapy for advanced osteosarcoma (Review). | Oncol Rep | 2017 | https://conductscience.org/library/papers/28656259 | PubMed |
| 3 | 20217247 | Soft tissue sarcoma of extremities: the prognostic significance of adequate surgical margins in primary operation and reoperation after recurrence. | Ann Surg Oncol | 2010 | https://conductscience.org/library/papers/20217247 | PubMed |
| 4 | 28660302 | Tumor angiogenesis and vascular normalization: alternative therapeutic targets. | Angiogenesis | 2017 | https://conductscience.org/library/papers/28660302 | PubMed |
| 5 | 11533692 | Normalizing tumor vasculature with anti-angiogenic therapy: a new paradigm for combination therapy. | Nat Med | 2001 | https://conductscience.org/library/papers/11533692 | PubMed |
| 6 | 4332371 | Isolation of a tumor factor responsible for angiogenesis. | J Exp Med | 1971 | https://conductscience.org/library/papers/4332371 | PubMed |
| 7 | 32110053 | Safety and Efficacy of Chemotherapy Combined with Anlotinib Plus Anlotinib Maintenance in Chinese Patients with Advanced/Metastatic Soft Tissue Sarcoma. | Onco Targets Ther | 2020 | https://conductscience.org/library/papers/32110053 | PubMed |
| 8 | 18572972 | Potential combination chemotherapy approaches for advanced adult-type soft-tissue sarcoma. | Am J Clin Dermatol | 2008 | https://conductscience.org/library/papers/18572972 | PubMed |
| 9 | 22648518 | Local recurrence of localized soft tissue sarcoma: a new look at old predictors. | Cancer | 2012 | https://conductscience.org/library/papers/22648518 | PubMed |
| 10 | 34281731 | Impact of histological subtype on radiological and pathological response after neoadjuvant radiotherapy in soft tissue sarcoma. | Eur J Surg Oncol | 2021 | https://conductscience.org/library/papers/34281731 | PubMed |
| 11 | 35912272 | Gemcitabine Plus Anlotinib Is Effective and Safe Compared to Gemcitabine Plus Docetaxel in Advanced Soft Tissue Sarcoma. | Front Oncol | 2022 | https://conductscience.org/library/papers/35912272 | PubMed |
| 12 | 21746804 | Phase IB study of the combination of docetaxel, gemcitabine, and bevacizumab in patients with advanced or recurrent soft tissue sarcoma: the Axtell regimen. | Ann Oncol | 2012 | https://conductscience.org/library/papers/21746804 | PubMed |
| 13 | 28499583 | Histotype-tailored neoadjuvant chemotherapy versus standard chemotherapy in patients with high-risk soft-tissue sarcomas (ISG-STS 1001): an international, open-label, randomised, controlled, phase 3, multicentre trial. | Lancet Oncol | 2017 | https://conductscience.org/library/papers/28499583 | PubMed |
| 14 | 24378391 | WHO classification of soft tissue tumours: an update based on the 2013 (4th) edition. | Pathology | 2014 | https://conductscience.org/library/papers/24378391 | PubMed |
| 15 | 26014294 | BEYOND: A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Phase III Study of First-Line Carboplatin/Paclitaxel Plus Bevacizumab or Placebo in Chinese Patients With Advanced or Recurrent Nonsquamous Non-Small-Cell Lung Cancer. | J Clin Oncol | 2015 | https://conductscience.org/library/papers/26014294 | PubMed |
| 16 | 15175435 | Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. | N Engl J Med | 2004 | https://conductscience.org/library/papers/15175435 | PubMed |
| 17 | 32181596 | Efficacy and safety of anlotinib, a multikinase angiogenesis inhibitor, in combination with epirubicin in preclinical models of soft tissue sarcoma. | Cancer Med | 2020 | https://conductscience.org/library/papers/32181596 | PubMed |
| 18 | 30231931 | Anlotinib: a novel multi-targeting tyrosine kinase inhibitor in clinical development. | J Hematol Oncol | 2018 | https://conductscience.org/library/papers/30231931 | PubMed |
| 19 | 33546021 | Impact of surgical margin on survival in extremity soft tissue sarcoma: A systematic review and meta-analysis. | Medicine (Baltimore) | 2021 | https://conductscience.org/library/papers/33546021 | PubMed |
| 20 | 29454091 | Anlotinib inhibits angiogenesis via suppressing the activation of VEGFR2, PDGFRβ and FGFR1. | Gene | 2018 | https://conductscience.org/library/papers/29454091 | PubMed |
Cited by6
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 6 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42614758 | Primary leiomyosarcoma of the lumbar soft tissue treated with multimodal therapy, including anlotinib: A case report. | Oncol Lett | 2026 | https://conductscience.org/library/papers/42614758 | PubMed |
| 42205857 | Drug-eluting bead transarterial chemoembolization combined with immune checkpoint inhibitors is associated with improved progression-free survival in locally advanced or metastatic sarcoma: a retrospective propensity score-matched analysis. | Ther Adv Med Oncol | 2026 | https://conductscience.org/library/papers/42205857 | PubMed |
| 41128656 | First-line Anlotinib plus Anthracyclines and Ifosfamide Followed by Anlotinib Maintenance in Advanced Soft-Tissue Sarcoma: A Phase II Single-Arm Trial. | Clin Cancer Res | 2026 | https://conductscience.org/library/papers/41128656 | PubMed |
| 39618078 | The Potential Therapeutic Targets of Anlotinib in Osteosarcoma: Characterization Based on Patient-Derived Xenografts and Next-Generation Sequencing. | Cancer Med | 2024 | https://conductscience.org/library/papers/39618078 | PubMed |
| 38967496 | Safety and efficacy of fruquintinib-based therapy in patients with advanced or metastatic sarcoma. | Cancer Med | 2024 | https://conductscience.org/library/papers/38967496 | PubMed |
| 38515149 | CircHAS2 activates CCNE2 to promote cell proliferation and sensitizes the response of colorectal cancer to anlotinib. | Mol Cancer | 2024 | https://conductscience.org/library/papers/38515149 | PubMed |
Genes4
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| KDR | 3791 | PubTator's text mining | https://conductscience.org/library/genes/3791 | NCBI Gene |
| KIT | 3815 | PubTator's text mining | https://conductscience.org/library/genes/3815 | NCBI Gene |
| TXK | 7294 | PubTator's text mining | https://conductscience.org/library/genes/7294 | NCBI Gene |
| VEGFA | 7422 | PubTator's text mining | https://conductscience.org/library/genes/7422 | NCBI Gene |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/36765658
GET https://conductscience.org/api/papers/v1/36765658/references?page=2